There is considerable overlap in morphologic features in well-differentiated hepatocellular lesions necessitating the use of immunohistochemistry and other techniques for diagnosis. Maplike pattern with glutamine synthetase in focal nodular hyperplasia and cytoplasmic staining with serum amyloid associated protein in inflammatory hepatocellular adenoma (HA) are useful for this distinction. The distinction of well-differentiated hepatocellular carcinoma (HCC) and HA in noncirrhotic liver is facilitated by demonstrating glypican-3 and cytogenetic changes like gains of chromosomes 1 and 8. Nuclear staining with b-catenin and/or diffuse staining with glutamine synthetase strongly favors welldifferentiated HCC or HA with high risk for HCC. In a cirrhotic liver, separation of early HCC from high-grade dysplastic nodule requires identification of stromal invasion, which can be highlighted by absence of keratin 7-positive ductular reaction. Combined use of heat shock protein 70, glutamine synthetase, and glypican-3 can be useful as positivity for 2 or more of these markers has shown high specificity for HCC in early studies.
FOCAL NODULAR HYPERPLASIA VERSUS HEPATOCELLULAR ADENOMA
FNH is thought to be a non-neoplastic lesion resulting from altered growth response secondary to abnormalities in blood flow. [1] [2] [3] FNH can often be diagnosed by modern imaging modalities. It is seen as a homogenous isoattenuating or slightly hypoattenuating liver mass on computed tomographic scan. It typically shows an immediate and intense enhancement during the arterial phase followed by isointensity of the lesion during the portal venous phase.
Typical magnetic resonance imaging findings include isointensity or hypointensity on T1-weighted images and the presence of a central scar that is hyperintense on T2weighted images. 4 Biopsy is usually performed only in cases with equivocal radiographic findings.
The typical histologic features of FNH include nodular architecture, central scar, ductular reaction, absence of interlobular bile ducts, and aberrant, thickwalled arterioles. The cell plates are 1 to 2 cells thick, but focally thick cell plates can be seen at the periphery. Most HAs do not show nodular architecture, central scar, or a prominent ductular reaction, but these features can occur in the inflammatory subtype of HA. Inflammatory HAs also characteristically show telangiectasia (sinusoidal dilatation), and were formerly classified as telangiectatic FNH. [5] [6] [7] [8] Clonality studies have shown that it is a monoclonal lesion, and clusters with HA in protein profiling studies. 9 Hence, this lesion was reclassified as inflammatory subtype of HA, a view that is reflected in the new World Health Organization classification. Although telangiectasia is a characteristic feature of inflammatory HA, it can be observed in FNH. The histologic overlap between inflammatory HA and FNH makes the distinction challenging on histologic grounds alone. As HA typically warrants surgical resection and surgical intervention is not usually necessary for FNH, the distinction between these 2 entities is crucial. Immunohistochemistry can be helpful in distinguishing between these 2 entities.
Glutamine Synthetase
Glutamine synthetase (GS) is an enzyme that plays a key role in nitrogen metabolism by converting glutamine from glutamate and ammonia. In the liver, it is expressed in the centrilobular regions, usually 1 or 2 hepatic plates thick around the central vein. 10 In FNH, large groups of hepatocytes express GS in an anastomosing manner, often surrounding hepatic veins and sparing the hepatocytes close to fibrotic bands ( Fig. 1A ). This has been referred to as geographic or "map-like" pattern, and is seen virtually in all cases of FNH. 11 Map-like pattern typical of FNH is not seen in HA. GS staining in HNF1a inactivated and inflammatory HA is either negative, stains hepatocytes around central veins similar to normal liver, or shows patchy staining, especially at the periphery (Fig. 1B) . The patchy staining can be mistaken for map-like pattern of FNH, but it is confined to the periphery and is not uniform or intense as in FNH. 12 b-catenin-activated HAs show diffuse and strong expression, due to upregulation of GS as a result of nuclear translocation of b-catenin. The diffuse pattern of staining is usually easily distinguished from the map-like pattern of FNH. Concomitant nuclear staining with b-catenin is also present in most HAs with diffuse GS staining (Tables 1, 2) .
Map-like pattern with glutamine synthetase in focal nodular hyperplasia (A). Patchy glutamine synthetase positivity at the periphery of inflammatory hepatocellular adenoma mimicking map-like pattern of focal nodular hyperplasia. This staining pattern is not as intense as in focal nodular hyperplasia and is seen only at the periphery (B). Cytoplamic granular positivity with serum amyloid associated protein in inflammatory hepatocellular adenoma (C). Cytoplasmic staining with glypican-3 in well-differentiated hepatocellular carcinoma (D). Nuclear translocation of b-catenin in b-catenin-activated hepatocellular adenoma (E). Diffuse cytoplasmic staining with glutamine synthetase in b-catenin-activated hepatocellular adenoma (F). Diffuse sinusoidal staining with CD34 in hepatocellular carcinoma. The sinusoids in non-neoplastic liver (upper half) are negative (G). Fluorescence in situ hybridization demonstrating increase copies of red signal in tumor cells indicating gains of chromosome 1. The tumor morphologically resembled hepatocellular adenoma, but recurred after 3 years (H).
b-Catenin
A subset of HAs (around 10%) show activation of b-catenin, which results in aberrant nuclear staining on immunohistochemistry. b-catenin mutation and nuclear immunohistochemical staining is not observed in FNH. 5, 7, 13 Serum Amyloid Associated Protein Most inflammatory HAs show strong cytoplasmic expression of serum amyloid associated (SAA) protein (Fig. 1C ). The expression can be patchy or diffuse. By quantitative reverse transcriptase polymerase chain reaction (RT-PCR), SAA is upregulated in inflammatory HA. The sensitivity and specificity of SAA immunohistochemistry for inflammatory HA is more than 90%. 5 C-reactive protein, another marker for inflammation, is also expressed in the cytoplasm. Around 10% of inflammatory HA also show b-catenin activation, with nuclear b-catenin and diffuse GS staining in addition to SAA positivity. Immunohistochemical staining with SAA protein is typically not observed in FNH, but patchy staining can be seen in around 10% of cases. SAA protein is commonly positive in non-neoplastic liver adjacent to mass lesions; this phenomenon can be observed with benign lesions like HA and FNH, and malignant neoplasms like HCC and metastatic carcinoma.
Keratin 7
Keratin 7 (K7) immunohistochemistry highlights the ductular reaction that can be seen in FNH and inflammatory HA, but is not seen in other subtypes of HA. In HAs, K7 stains singly scattered or small aggregates of hepatocytes. 14, 15 The small and intermediate-sized hepatocytes typically show the strongest staining, whereas the large mature hepatocytes are negative.
In summary, inflammatory HA shows significant morphologic overlap with FNH. Immunohistochemistry is very valuable in this distinction by demonstrating map-like staining with GS in FNH, and cytoplasmic staining with SAA in inflammatory HA (Table 1 ).
HEPATOCELLULAR ADENOMA VERSUS WELL-DIFFERENTIATED HEPATOCELLULAR CARCINOMA
It can be challenging to distinguish HA from welldifferentiated (WD)-HCC in noncirrhotic liver, especially when limited tissue is available for evaluation. The histologic features that favor HCC include wide cell plates (>3 cells thick), loss of the reticulin framework, pseudoacinar architecture, small cell change, cytologic atypia, mitotic activity, and vascular invasion. However, many of these features may be absent in WD-HCC, and features such as focal pseudoacinar architecture and nuclear atypia can be occasionally seen in HA. The distinction can be especially challenging when tumors morphologically resembling HA occur in atypical clinical settings like in men or older women. Some HA-like tumors occurring in these settings have been reported to recur and/or metastasize, and may represent extremely well-differentiated variants of HCC. 16 This differential diagnosis is clinically relevant as the prognosis and follow-up of HA and HCC are different. Several ancillary techniques have been described in recent years that can be helpful in this differential diagnosis.
Glypican-3
Glypican-3 (GPC-3) is a membrane anchored heparin sulfate proteoglycan normally expressed in fetal liver and placenta, but not in normal adult liver. It is an oncofetal antigen that is a reliable serum and histochemical marker for HCC. [17] [18] [19] GPC-3 expression is also characteristically seen in yolk sac tumor and choriocarcinoma. Earlier studies described GPC-3 expression in melanomas in up to 80% of cases, but more recent studies have observed in <10% of cases. [20] [21] [22] [23] [24] GPC-3 staining has been reported in 70% to 90% of HCCs in most studies, [25] [26] [27] [28] [29] and is more sensitive than Hep Par 1 for the identification of poorly differentiated HCC. 26 GPC-3 can be useful in this differential diagnosis as it is negative in HA. 18, [26] [27] [28] The sensitivity of GPC-3 in 34 These tumors are characterized by inflammation, telangiectasia, and ductular reaction. (Fig. 1E) . b-catenin mutations are seen in approximately 20% of HCCs, and in up to 40% of HCCs arising in the setting of hepatitis C. 36 The new classification creates a category of b-cateninactivated adenomas that often occur in men and show atypical morphologic features and are associated with HCC at diagnosis or follow-up. Preliminary studies have shown that these tumors often show cytogenetic changes typical of HCC and may be associated with recurrence and/or metastasis in some cases. 37 Although these tumors are categorized as HA in the current World Health Organization classification, it remains to be clarified whether these tumors represent high-risk HA or extremely well-differentiated variants of HCC. GS is one of the genes that is upregulated as a result of nuclear translocation of b-catenin. Hence, GS immunohistochemical staining shows strong and diffuse expression in tumors with abnormalities in the b-catenin pathway (Fig. 1F ). 32 In normal liver, GS expression is limited to 1 to 2 hepatic plates around the central vein. There is high concordance between nuclear b-catenin staining and diffuse GS staining. Some cases with diffuse and strong GS expression lack nuclear b-catenin staining and the reason for this discrepancy is not clear. It may be a result of b-catenin mutations without nuclear b-catenin staining, or other mutations in the Wnt signaling pathway. As nuclear b-catenin can be focal and difficult to interpret, diffuse GS expression is a more reliable indicator of abrogation of b-catenin.
CD34
In normal liver, CD34 stains the vessels of the portal tract and the sinusoids immediately adjacent to the portal tract, whereas most of the sinusoids are negative. 38 In HCC, there is a phenotypic change in the vasculature resulting in diffuse sinusoidal CD34 positivity (capillarization of the hepatic sinusoids, Fig. 1G ). Increased sinusoidal staining is also seen in benign hepatocellular lesions such as HA and FNH, but is typically patchy. However, there is sufficient overlap between the patterns observed in HCC and HA, making CD34 less diagnostically useful. 39 CD34 can be helpful to confirm the presence of lesional tissue when dealing with limited liver biopsy specimens.
Chromosomal Analysis
HCCs show a consistent pattern of cytogenetic gains and losses. 40, 41 The most common abnormalities include gains of 8q (49% to 81%), 1q (60% to 79%), and 7q (40% to 64%), and loss of 16q (36% to 65%). Gains of part or the entire chromosome arm of 1q and 8q are the most common abnormalities and are believed to be associated with early development of HCC.
Using either fluorescence in situ hybridization or comparative genomic hybridization, several studies have demonstrated that the most common cytogenetic abnormalities seen in early HCC, most notably gains in 1q and 8q, are typically not observed in HA occurring in women in the reproductive age group. 16, [42] [43] [44] [45] Tumors resembling HA that occur in men or women >50 years can show gains of 1q and 8q similar to WD-HCC (Fig. 1H ), and may recur or metastasize. 16 Hence, it may be prudent to use the term "well-differentiated hepatocellular neoplasm" for HA-like neoplasms that occur in men and older women, especially on a core biopsy.
Gene Expression
Differential gene expression in HA and HCC has been shown, 46 with further validation by RT-PCR and immunohistochemistry. These genes include insulin growth factor-II, clusterin, and estrogen receptor. This technique and the genes identified by it have not been studied more widely and its practical utility has yet to be established.
In summary, the most useful ancillary tools in the setting of a well-differentiated hepatocellular neoplasm in a noncirrhotic liver are GPC-3, b-catenin, and GS. Expression of GPC-3, nuclear staining with b-catenin, and/or diffuse staining with GS strongly favors well-differentiated HCC. Fluorescence in situ hybridization studies for 1q and 8q, although not widely available, can be valuable in the distinction of HA and WD-HCC.
HIGH-GRADE DYSPLASTIC NODULE VERSUS WELL-DIFFERENTIATED HEPATOCELLULAR CARCINOMA
Nodules in a cirrhotic liver that are >2 cm and show typical imaging findings of arterial hypervascularity with venous washout on triphasic computed tomography or magnetic resonance imaging are easily diagnosed as HCC. [47] [48] [49] [50] On the basis of the American Association for the Study of Liver Diseases criteria, the diagnosis of HCC can be established in these cases based on imaging and a biopsy is needed only if the radiologic findings are not typical. Small HCCs (<2 cm), however, are often hypovascular and do not show typical imaging findings.
Liver biopsy is necessary to establish the diagnosis in these cases.
Small HCCs (<2 cm) can be divided into 2 distinct groups. [51] [52] [53] The first group has been referred to as early HCC, vaguely nodular HCC, or very well-differentiated HCC. They are characterized by a vaguely nodular gross appearance, are extremely well-differentiated, and difficult to distinguish from HGDN. The second group, progressed HCC, shows a distinct nodular pattern, has clearly thickened hepatic plates, and is thus usually easily recognized as HCC.
The term dysplasia is used to describe a population of cells that display histologic characteristics of abnormal growth caused by presumed genetic alterations without fulfilling definite criteria of malignancy. 54 A cluster of dysplastic hepatocytes that is recognized microscopically (<1 mm in diameter) is referred to as dysplastic focus, whereas larger lesions (usually >1 mm) that are grossly or radiologically apparent are designated as dysplastic nodule. Low-grade dysplastic nodule is a clonal proliferation, but is difficult to distinguish from large regenerative nodules on morphologic grounds. Hence, this term is rarely used in diagnostic pathology. HGDN is characterized by small cell change, but unlike progressed HCC the cell plates are <3 cells thick, portal tracts are present, and there is no or minimal loss of reticulin network. Unpaired arterioles and pseudoacinar architecture can be present, but are not as prominent as in HCC. Hence, the difference between HGDN and HCC often tends to be quantitative leading to high degree of subjectivity and interobserver variability.
The differentiation of HGDN from early HCC is extremely difficult and may be impossible on a biopsy. The features that favor HCC such as uniformly thick cell plates, prominent pseudogland formation, and loss of the reticulin framework are often absent in early HCC. Vascular space invasion is diagnostic of HCC, but is not typically identified in early lesions. Stromal invasion is the most reliable feature to distinguish early HCC from HGDN, but this is often difficult to assess on small core biopsies. Stromal invasion refers to invasion of abnormal hepatocytes into perinodular portal tracts, fibrous septa, or adjacent parenchyma, and is considered a diagnostic feature of HCC. [50] [51] [52] [53] Stromal invasion can also be intranodular with invasion of portal tracts within the nodule.
An unequivocal diagnosis of small HCC has several clinical implications. Small HCCs have a higher likelihood of cure and it allows for definitive therapy such as resection or ablation. Appropriate diagnosis also allows the patient to be appropriately prioritized for liver transplantation. In contrast, it is also important not to subject patients with HGDN to invasive treatment as these can spontaneously regress. 50, 53 As imaging is not reliable for these small nodules, a liver biopsy is often indicated. The following ancillary tools have been used to help in this differential diagnosis.
Keratin 7
In cirrhosis, small groups of hepatocytes (hepatocyte buds) can be surrounded by fibrous septa, mimicking stromal invasion ( Fig. 2A) . These intraseptal buds are contiguous with the adjacent ductular reaction and are indicative of a regenerative phenomenon. This ductular reaction can be highlighted by a K7 immunohistochemical stain (Fig. 2B) . In areas of stromal invasion by early HCC, this ductular reaction is absent on K7 staining. A recent study shows that >95% of HGDN showed significant K7 ductular staining at the nodule interface, whereas focal and diffuse loss of K7-positive ductular reaction is seen in early and progressed HCC, respectively (Fig. 2C, D) . 55 
CD34
Typically, there is focal CD34 staining at the periphery of a HGDN, whereas HCC will show more diffuse staining. 56 This progression of capillarization of the sinusoids is consistent with the premalignant potential of HGDN. However, there is significant overlap between CD34 patterns and this may not be useful in individual cases.
Heat Shock Protein 70
Heat shock proteins (HSPs) are highly conserved proteins and play an important role in the regulation of cell cycle progression and apoptosis. HSPs are classified according to their molecular weight. HSP70 is an antiapoptotic protein and its overexpression allows cell survival. In 1 study, comparing gene expression between HCC and other hepatocellular nodules, a set of 95 genes provided the molecular signature that distinguished early HCC from nonmalignant tissue. Among these 95 genes, HSP70 was the most discriminatory between HCC and non-HCC liver. Several studies have attempted to use HSP70 immunohistochemical staining to distinguish HGDN from early HCC ( Fig. 2E, F) . [57] [58] [59] [60] [61] HSP70 staining is seen in up to 80% of early HCCs in resection specimens, but in <50% of cases on biopsy. HSP70 expression has also been seen in 5% to 10% of HGDN.
Glypican-3
GPC-3 is an oncofetal protein that is expressed in the majority of HCCs but is not yet reported in any HAs. The specificity of GPC-3 is not as robust in the setting of cirrhosis. The expression of GPC-3 in HGDN varies in many studies ranging from 7% to 43%. [25] [26] [27] 58 Other pitfalls in diagnosis include patchy GPC-3 expression in cases with high necroinflammatory activity 62 and patchy staining in 4% of regenerative cirrhotic nodules. 26 
Glutamine Synthetase
GS is upregulated as a result of nuclear translocation of b-catenin. Hence, diffuse GS staining strongly correlates with activation of b-catenin. Diffuse GS expression has been reported in 13% to 70% of early HCC and expression can be seen in 10% to 15% of HGDN. In contrast to the diffuse expression seen in HCC, GS expression in HGDN is typically focal. 58, 61 Combined Use of Heat Shock Protein 70, Glypican-3, and Glutamine Synthetase Two studies from Di Tommaso et al 58 have evaluated the combined use of all 3 markers in biopsy specimens and resection specimens, respectively. 59 The specificity and sensitivity for the diagnosis of HCC was 100% and 57%, respectively when any 2 of 3 markers were positive (Fig. 2G, H) . All 3 stains were negative in >70% of HGDN compared with 3% of early HCC in resection specimens, whereas all 3 were positive in 43% of early HCC compared with none of the HGDN. Hence, based on these initial studies, the combined use of these 3 markers is useful for diagnosis of HCC when at least 2 are positive ( Table 3) . 
Cyclase-associated Protein 2
Cyclase-associated protein 2 plays a role in the RAS pathway and is involved in cytoskeletal function through binding with actin. It is strongly expressed in smooth muscle but is negative in normal liver. 61 Most HGDN are negative or focally positive, whereas 40% of early HCCs show staining in 70% of tumor cells. This marker has not been widely studied in the diagnostic setting.
Gene Expression
RT-PCR has shown different gene expression profiles for HGDN and early HCC. 63, 64 In 1 study, 12 genes were differentially expressed in early HCC compared with HGDN. A 3-gene set including GPC-3, lymphatic vessel endothelial receptor, and survivin had a discriminatory accuracy of 94%. 63 This technique is useful for identifying potential markers for HCC, but is too cumbersome for routine use.
In summary, the distinction between HGDN and early HCC continues to be a challenging problem on needle biopsy. K7 can be useful to demonstrate stromal invasion, whereas combined use of HSP70, GPC-3, and GS has shown to be a useful ancillary tool. Further studies are necessary before the use of these markers can be recommended for routine use. 
